08:00 , Feb 11, 2010 |  BC Innovations  |  Tools & Techniques

Synthetic saponins

Memorial Sloan-Kettering Cancer Center researchers have designed vaccine adjuvants that are synthetic derivatives of Antigenics Inc. 's QS-21, 1 a purified fraction of a plant extract containing a mixture of two natural saponin isomers. The...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

Antigenics, J&J deal

Johnson & Johnson's newly formed subsidiary Janssen Alzheimer Immunotherapy will now have rights to manufacture Antigenics' adjuvant QS-21 for development and commercialization of ACC-001 under an amended 2000 deal. In return, Antigenics will receive an...
07:00 , Jul 10, 2006 |  BioCentury  |  Strategy

Stimulating deals

Looking to boost the response to its cancer vaccines, Antigenics Inc. acquired Aquila Biopharmaceuticals Inc. in 2000 for $40 million in stock. Since then, AGEN has monetized over $20 million of the deal, in large...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Company News

NeurogesX management update

NeurogesX Inc. , San Carlos, Calif.   Business: Neurology   Hired: Jeffery Tobias as CMO, formerly a principal at Aquila Consulting Group LLC  ...
08:00 , Mar 22, 2004 |  BC Week In Review  |  Company News

Antigenics, Virbac S.A. deal

AGEN sold to Virbac the manufacturing rights to its feline leukemia virus (FeLV) vaccine for $14.3 million in cash. Virbac already holds exclusive worldwide marketing rights to the vaccine, which AGEN gained through its 2000...
07:00 , Apr 30, 2001 |  BioCentury  |  Strategy

Acquiring a Pipeline

Acquiring a Pipeline When Antigenics Inc. acquired Aquila Biopharmaceuticals Inc. last year, AGEN added several immune stimulation products to its pipeline. With last week's acquisition of Aronex Pharmaceuticals Inc. , AGEN believes it has addressed...
07:00 , Apr 30, 2001 |  BioCentury  |  Strategy

Acquiring a Pipeline

Acquiring a Pipeline When Antigenics Inc. acquired Aquila Biopharmaceuticals Inc. last year, AGEN added several immune stimulation products to its pipeline. With last week's acquisition of Aronex Pharmaceuticals Inc. , AGEN believes it has addressed...
08:00 , Mar 19, 2001 |  BC Week In Review  |  Clinical News

Globo H vaccine: Phase I

Researchers at the institute reported in the Proceedings of the National Academy of Sciences that in a U.S. Phase I study of a globo H vaccine used with QS-21 adjuvant in 27 women with metastatic...
08:00 , Dec 18, 2000 |  BioCentury  |  Tools & Techniques

Malaria vaccine pipeline

Malaria vaccine pipeline Company Partner Type of vaccine Antigen Adjuvant Phase Vical (VICL) Aventis (AVE), USNMRC DNA Multiple GM-CSF Phase II Aquila (AQLA) SmithKline Beecham Peptide RTS,S and TRAP (sporozoite) QS-21 Phase I/II Imperial College...
08:00 , Dec 18, 2000 |  BioCentury  |  Tools & Techniques

Getting interested in malaria

The biotechnology industry has long ignored troublesome, endemic diseases of developing countries such as malaria. But the ever-increasing number of airline travelers who become infected during trips and the appearance of previously foreign diseases in...